ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $2.67 billion. The enterprise value is $3.35 billion.
Important Dates
The last earnings date was Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 945.25 million shares outstanding. The number of shares has increased by 25.42% in one year.
| Current Share Class | 945.25M |
| Shares Outstanding | 945.25M |
| Shares Change (YoY) | +25.42% |
| Shares Change (QoQ) | +4.11% |
| Owned by Insiders (%) | 43.07% |
| Owned by Institutions (%) | 10.43% |
| Float | 193.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.50 |
| Forward PS | 27.61 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 59.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.11
| Current Ratio | 4.11 |
| Quick Ratio | 3.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -42.14% |
| Return on Invested Capital (ROIC) | -62.10% |
| Return on Capital Employed (ROCE) | -81.20% |
| Revenue Per Employee | $83,235 |
| Profits Per Employee | -$539,841 |
| Employee Count | 680 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.05 |
Taxes
In the past 12 months, ImmunityBio has paid $35,000 in taxes.
| Income Tax | 35,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.20% in the last 52 weeks. The beta is -0.07, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -36.20% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 59.28 |
| Average Volume (20 Days) | 9,042,800 |
Short Selling Information
The latest short interest is 77.07 million, so 8.15% of the outstanding shares have been sold short.
| Short Interest | 77.07M |
| Short Previous Month | 76.98M |
| Short % of Shares Out | 8.15% |
| Short % of Float | 39.82% |
| Short Ratio (days to cover) | 10.42 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $56.60 million and -$367.09 million in losses. Loss per share was -$0.49.
| Revenue | 56.60M |
| Gross Profit | 56.41M |
| Operating Income | -285.37M |
| Pretax Income | n/a |
| Net Income | -367.09M |
| EBITDA | -269.07M |
| EBIT | -285.37M |
| Loss Per Share | -$0.49 |
Full Income StatementBalance Sheet
The company has $153.66 million in cash and $842.67 million in debt, giving a net cash position of -$689.01 million or -$0.73 per share.
| Cash & Cash Equivalents | 153.66M |
| Total Debt | 842.67M |
| Net Cash | -689.01M |
| Net Cash Per Share | -$0.73 |
| Equity (Book Value) | -569.82M |
| Book Value Per Share | -0.62 |
| Working Capital | 157.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$349.56 million and capital expenditures -$7.11 million, giving a free cash flow of -$356.66 million.
| Operating Cash Flow | -349.56M |
| Capital Expenditures | -7.11M |
| Free Cash Flow | -356.66M |
| FCF Per Share | -$0.38 |
Full Cash Flow StatementMargins
| Gross Margin | 99.66% |
| Operating Margin | -504.18% |
| Pretax Margin | -648.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.42% |
| Shareholder Yield | n/a |
| Earnings Yield | -13.77% |
| FCF Yield | -13.38% |
Analyst Forecast
The average price target for ImmunityBio is $10.20, which is 304.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.20 |
| Price Target Difference | 304.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 142.71% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -12.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.58 |
| Piotroski F-Score | 4 |